OBiO Tech(SH:688238) Zheng Quan Ri Bao·2025-04-23 22:55Core Viewpoint - The company reported a decline in total revenue for the first quarter of 2025, with specific segments showing varied performance, indicating challenges in the CDMO business while maintaining growth in CRO and other services [7][8]. Financial Performance - The company achieved total revenue of 52.84 million yuan, a decrease of 11.29% compared to the same period last year [7]. - Revenue from cell and gene therapy CRO services was 19.86 million yuan, reflecting a growth of 10.59% year-on-year [7]. - Revenue from cell and gene therapy CDMO services was 27.61 million yuan, down 27.74% year-on-year, primarily due to the types of CDMO orders executed and the progress of different projects [7]. - Other main business segments, including research reagents and cell storage services, generated revenue of 5.36 million yuan, an increase of 60.26% year-on-year [7]. Business Development - The company secured over 28 million yuan in new CDMO orders during the reporting period [7]. - It assisted clients in obtaining two IND approvals in the US and China, including one from the FDA, bringing the total to 46 approvals across multiple countries, with 13 from the FDA [7]. Intellectual Property - The company and its subsidiaries registered three new domestic trademarks and one copyright, and applied for two invention patents and six utility model patents during the reporting period [8]. - As of the end of the reporting period, the company held a total of 27 invention patents, 16 utility model patents, 2 design patents, 1 software copyright, 8 works copyrights, 65 domestic trademarks, and 4 international trademarks [8]. Share Buyback - On February 13, 2025, the company approved a share buyback plan to repurchase its A-shares using its own funds and a special loan for stock repurchase [9]. - As of April 10, 2025, the company completed the buyback of 18,726,690 shares, with a total expenditure of approximately 99.94 million yuan [10].